| Literature DB >> 22243671 |
Nathan P King1, Türkan Sakinç, Nouri L Ben Zakour, Makrina Totsika, Begoña Heras, Pavla Simerska, Mark Shepherd, Sören G Gatermann, Scott A Beatson, Mark A Schembri.
Abstract
BACKGROUND: The Gram-positive bacterium Staphylococcus saprophyticus is the second most frequent causative agent of community-acquired urinary tract infections (UTI), accounting for up to 20% of cases. A common feature of staphylococci is colonisation of the human skin. This involves survival against innate immune defenses including antibacterial unsaturated free fatty acids such as linoleic acid which act by disrupting bacterial cell membranes. Indeed, S. saprophyticus UTI is usually preceded by perineal skin colonisation.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22243671 PMCID: PMC3398289 DOI: 10.1186/1471-2180-12-8
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Figure 1Structure of the . Arrows represent CDS coloured according to their predicted function: no specific function (light blue); replication (pink); transposase for IS431 (yellow); other transposase (orange); integrase (brown); virulence-related (red); hypothetical protein (grey); and pseudogenes (black). Similarity regions between sequences are coloured in a gradient of blue, reflecting the percentage of nucleotide identity ranging from 91 to 100%, as illustrated on the scale on the top right of the figure.
Figure 2Sequence analysis of SssF. (A) Primary structure of the S. saprophyticus MS1146 SssF protein. The putative signal peptide, the corresponding gene region used for PCR screening, the region used in the multiple alignment (Additional file 2: Figure S1), the region used for polyclonal antibody raising and the LPDTG sortase anchor motif are indicated. (B) Structural prediction of the mature form of SssF. Residues coloured in red and in blue are predicted to adopt α-helical and β-strand conformations respectively. (C) Crystal structures of tropomyosin and alpha-actinin identified as likely structurally similar to SssF.
Figure 3Expression of SssF. (A) Western blot analysis of whole-cell lysates prepared from S. saprophyticus MS1146, MS1146sssF and MS1146sssF(pSssF) using a polyclonal antiserum directed against SssF. Lanes: M, Novex Sharp Pre-stained protein marker (Invitrogen); 1, MS1146; 2, MS1146sssF; 3, MS1146sssF(pSssF). The position of SssF is indicated. Expression of SssF was detected in wild-type S. saprophyticus strain MS1146 and the sssF complemented strain but not in the isogenic sssF mutant. (B) Immunogold TEM of S. saprophyticus MS1146, MS1146sssF and MS1146sssF(pSssF). Expression of SssF at the cell surface of S. saprophyticus MS1146 was demonstrated by abundant labeling with SssF-gold particles. In contrast, the sssF isogenic knockout mutant was devoid of gold labeling. Complementation of the sssF mutation restored and enhanced surface expression of SssF. Bars, 500 nm.
Figure 4Agar plate-based linoleic acid survival assay. Relative survival of sssF+ (including MS1146) and sssF- S. saprophyticus strains on BHI agar medium supplemented with 0.85 M NaCl and containing 0 mM (A) or 5 mM (B) linoleic acid. The presence of the sssF gene is associated with increased (30-fold) resistance to linoleic acid. Serial dilutions of overnight S. saprophyticus cultures (2.5 μl) were spotted onto BHI agar + 0.85 M NaCl, containing 0 mM and 5 mM linoleic acid, 1% ethanol. The neat to 10-5 dilutions are as indicated.
Figure 5SssF activity is detected in a . (A) Relative survival of S. aureus SH1000 wild-type, SH1000sasF isogenic mutant and sasF, sssF and vector only complemented strains on agar medium containing 1 mM linoleic acid. Heterologous complementation of the S. aureus SH1000 sasF mutant with the sssF gene from S. saprophyticus MS1146 restores survival in these conditions. Serial dilutions of overnight S. aureus cultures (2.5 μl) were spotted onto BHI agar, pH 6.0, containing 0 mM and 1 mM linoleic acid, 1% ethanol. The neat to 10-6 dilutions are as indicated. Shown are representative images from one of multiple experiments. (B) Graph showing the relative survival of S. aureus SH1000 and SH1000 derivates using data from Figure 5A. Colonies were counted after overnight incubation. Error bars represent ± SEM. Results from multiple experiments were analysed with Student's t test.
Strains and plasmids used in this study
| Strain or plasmid | Description | Reference or source |
|---|---|---|
| DH5α | F- φ80d | Grant |
| BL21 | F- | Stratagene |
| MS2066 | DH5α containing pSssFHis | This study |
| MS2067 | BL21 containing pSssFHis | This study |
| ATCC 15305 | Type strain (genome sequenced) | Kuroda |
| MS1146 | Clinical isolate | AstraZeneca |
| MS1146 | MS1146 isogenic | This study |
| MS1146 | Complemented MS1146 | This study |
| SH1000 | Functional | Horsburgh |
| SH1000 | SH1000 isogenic | This study |
| SH1000 | SH1000 | This study |
| SH1000 | SH1000 | This study |
| SH1000 | SH1000 | This study |
| TM300 | Wild-type SK311 | Schleifer & Fischer [ |
| TM300(pSssF) | TM300 containing pSssF | This study |
| pBAD/HisB | Cloning and protein expression vector, containing N-terminal 6 × His tag; Apr | Invitrogen |
| pNL9164 | Sigma | |
| pSK5632 | Cloning and expression | Grkovic |
| pPS44 | Staphylococcal vector, contains replicon and | Wieland [ |
| pSssFHis | 1330 bp MS1146 | This study |
| pNK24 | pNL9164 shuttle vector retargeted with primers 1001-1003, EBSU to knock out MS1146 | This study |
| pNK41 | pNL9164 shuttle vector retargeted with primers 2065-2067, EBSU to knock out SH1000 | This study |
| pSKSssF | 2394 bp fragment, including entire | This study |
| pSssF | 2400 bp BamHI/XbaI fragment, containing | This study |
| pSKSasF | 2175 bp fragment, including | This study |
PCR primers used in this study
| Primer | Sequence (5'-3') | Description |
|---|---|---|
| 1127 | GTTGAAGCAATATTGAAGAAAGC | |
| 1128 | TTCTTCATTTAGTTTACCCATATCAAC | |
| 839 | GCTA | |
| 840 | ACTA | |
| 873 | GCTCA | |
| 874 | GCTCG | |
| 1001 | AAAAAAGCTTATAATTATCCTTAAGTCACTACTATGTGCGCCCAGATAGGGTG | |
| 1002 | CAGATTGTACAAATGTGGTGATAACAGATAAGTCTACTATCTTAACTTACCTTTCTTTGT | |
| 1003 | TGAACGCAAGTTTCTAATTTCGATTTGACTTCGATAGAGGAAAGTGTCT | |
| 2065 | AAAAAAGCTTATAATTATCCTTATCGTACGGCAAGGTGCGCCCAGATAGGGTG | |
| 2066 | CAGATTGTACAAATGTGGTGATAACAGATAAGTCGGCAAGATTAACTTACCTTTCTTTGT | |
| 2067 | TGAACGCAAGTTTCTAATTTCGGTTTACGATCGATAGAGGAAAGTGTCT | |
| 2084 | CAGT | |
| 2085 | CCGT | |
| 1011 | TTCTTTAGGTGATGAACATATCAGG | Sequencing primer to check for correct 350 bp retargeted intron fragments for TargeTron |
| EBSU | CGAAATTAGAAACTTGCGTTCAGTAAAC | TargeTron EBS universal |